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Coronary artery bypass graft surgery is a high-risk surgical intervention and commonly 
accounts for hospital readmissions within 30 days of discharge. Pleural effusions that 
require therapeutic thoracentesis are a reason for many of the readmissions. Studies have 
examined the adverse clinical effects that large volume pleural effusions have in these 
patients. However, effusion volume itself may have little influence on patient outcomes.   
Complications occur without close monitoring and drainage. In this study, we propose a 
randomized controlled trial to determine whether frequent follow-up and drainage 
of pleural effusions ≥320 ml can improve the need for rehospitalization and 
influence 6-minute walk tests in patients undergoing coronary artery bypass 
surgery. We hypothesize that these two interventions will decrease hospital readmission 
rates and improve 6-minute walk tests in patients within 30 days of hospital discharge. 
Insights from this study may ultimately help improve the management of coronary artery 







Chapter 1 – Introduction 
1.1 Background 
 Coronary artery bypass (CABG) surgery, one of the most expensive and often 
performed surgical procedures, is associated with the need for frequent hospital 
readmissions1. Studies have shown that 12.9%-24% of patients undergoing CABG 
require hospital readmission and that 80.6% of these occur within 30 days of discharge2-4. 
With the expectation that hospital reimbursements will soon be linked to clinical 
outcome, the importance of reducing 30-day hospital readmission rates has been 
emphasized in efforts to lower expenditures5. Furthermore, early readmissions following 
cardiac procedures have been shown to result in more than 3% mortality during 
hospitalization. With an estimated 600,000 people undergoing CABG surgery in the US 
each year, a reduction in hospital readmissions in this population would have a profound 
impact on both hospitals and patients6. 
 Many studies have been performed to examine if earlier follow-up after discharge 
can reduce these hospitalizations. The results have been widely conflicting. While some 
studies show increased follow-up may lead to a reduction in 30-day readmissions by up 
to 66% and with it a reduction in hospital cost by 50%7,8, others demonstrate no 
benefit9,10. 
 In a study of 1,205 CABG patients, 40% of readmitted patients were hospitalized 
for three days or less, suggesting that many of these cases were preventable1. 
Postoperative pulmonary complications are a leading cause of CABG-associated 
morbidity11,12. Of CABG rehospitalizations within 30 days, up to 23% are due to pleural 
effusions requiring drainage1,2,4. These high readmission rates identify a need for 
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different management strategies and reveal an unstudied area where a change in practice 
may lead to improved patient outcomes13. 
1.2 Pleural Effusion Morbidity 
Pleural effusions are extremely common in CABG patients, with incidence rates 
of 40-95% within thirty days following surgery11,14-17. Early effusions are usually bloody, 
caused by trauma from the surgery with bleeding into the pleural space, phrenic nerve 
injury, disruption of pleural lymphatic drainage by internal mammary artery harvesting, 
poor chest wall compliance, and diaphragm dysfunction18. These effusions range from 
small, occupying less than one intercostal space, to large, with as many as 10% 
occupying more than a quarter of the hemithorax. Regardless of size, symptoms may 
range from asymptomatic to dyspnea, cough, chest pain, and insomnia16,19.  Many studies 
have focused on the adverse effects that ensue from larger (>1000ml) effusions, which 
include atelectasis, arrhythmias, cardiac tamponade, and ventricular diastolic 
collapse15,20-22. Aside from hemodynamic changes, pleural effusions can also affect gas 
exchange, sleep patterns, walking distance measured by the 6-minute walk test (6MWT), 
and pulmonary function tests, among others21,23,24.   These side effects from effusions 
result in lower recovery rates and increase the need for bed rest, which further puts 
patients at risk for edema, venous thromboembolism, and pneumonia. Recent literature 
however has provided evidence that volume of effusion is poorly correlated to clinical 
impact, suggesting that small volume pleural effusions can be equally hazardous to 
patient outcomes15,25.   
Patients with pleural effusions undergoing thoracentesis have been documented to 
yield shorter ICU and hospital stays, which is correlated to lower 30-day readmission 
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rates5,20,26. Although there are no formal guidelines in place regarding the treatment of 
pleural effusion due to CABG, historical recommendations are that large or symptomatic 
pleural effusions should be managed with therapeutic thoracentesis at the discretion of 
the physician6,15,27-29.   This practice may be called into question since neither the 
symptoms, such as shortness of breath, nor limitations in physical activity are directly 
related to volume of effusion30. With no data suggesting that small effusions are 
qualitatively different from clinically detectable ones, recommendations for thoracentesis 
may be applied to these patients as well. 
Ultrasound has been associated with better sensitivity and specificity for 
diagnosing and quantifying pleural effusions when compared to chest radiograph and 
does not pose any risk to the patient20,31,32. When performed using ultrasound, 
thoracentesis is widely regarded as a safe procedure26. In a study of 9,320 thoracenteses, 
the overall complication rate was 0.98% with no mortality. Complications included 
pneumothorax, pulmonary edema, and bleeding episodes, all of which were acutely 
managed33. Thoracenteses may be performed as an outpatient procedure, and are 
associated with low financial cost aside from the patient and clinician time15,25. 
Therapeutic aspirations for pleural effusions are associated with an immediate 
improvement in symptoms such as dyspnea and fatigue as well as a return to baseline in 
6-minute walk tests, exercise tolerance, total sleep time, expiratory flow, and 
circulation14,19,23,24,34,35. Similar to above, the amount of fluid drained does not correlate 
with a relief of symptoms or return to baseline. As such, a clear “clinical cut-off volume” 
recommended for drainage does not exist. However, bedside ultrasound has been used 
and shown to be reliable in estimating the volume of pleural effusion present. 
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Thoracentesis was routinely, and safely, performed in one study in whom 500 ml of fluid 
was thought to be present using the algorithm: Volume = [16 x D] where D represented 
the distance between the mid-height of the diaphragm and the visceral pleura in end-
expiration. In this study, it was suggested that pleural separations below 20mm (320ml 
effusion size) seen on ultrasound are less clinically significant and more likely to self-
resolve36. 
 Early diagnosis of pleural effusion may have a significant role in preventing 
readmissions1,20. While two-thirds of pleural effusions occur during initial 
hospitalization, one-third occurs after discharge and all have a potential to cause 
complications if left untreated37. Standard CABG postoperative protocols involve an 
exam of the patient one day before surgery, a chest x-ray two days after surgery, and a 
second exam after 25-30 days15. In a prospective evaluation of patients readmitted after 
cardiac procedures, interventions such as thoracenteses were commonly performed within 
the first two weeks of hospital discharge, suggesting the need for follow-up within this 
time period38.  
In a recently published case series, a hospital’s cardiothoracic surgery team was 
alerted to any early post-CABG patient presenting to the emergency department, allowing 
the team to assess the patient and determine if their condition could be managed without 
readmission. The high frequency of pleural effusions seen prompted the creation of an 
outpatient thoracentesis program, which was shown to contribute to a reduction in 30-day 
readmissions at the hospital39. Additionally, a randomized, controlled trial allocated 
patients to more frequent follow-up within 30 days after CABG discharge and included a 
lowered, standardized threshold for thoracentesis procedures in pleural effusions. Patients 
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in the intervention group were examined at days 3-4 and 10-15 and therapeutic 
aspirations were performed with estimated pleural effusions of 400ml or symptoms of 
respiratory distress. This group found unrecognized pathology in more than 20% of 
patients during additional visits and resulted in an increase of 15% in physical recovery 
rate, as measured by change in patient walking distance. No other controlled studies have 
examined the effect of thoracentesis on patients after CABG surgery, and the effects on 
hospital readmissions has yet to be determined15. 
1.3 The role of the Six-Minute Walk Test (6MWT) and modified BORG Dyspnea 
Scale (mBORG) 
 The 6MWT has been used to assess how the cardiopulmonary system responds to 
mild exercise, and it had been found to be an indicator of how well the patient will 
tolerate daily activities outside the hospital19. In addition to measuring the distance a 
person can walk in 6 minutes, this test also reveals concurrent oxygenation and heart rate. 
It is often paired with the modified BORG dyspnea scale (mBORG), in which the patient 
assesses the amount of breathlessness experienced both at rest and during peak levels 
evoked during the test19,40. Associations between 6MWT and treadmill exercise tests have 
been made, and improvements in distance walked have been correlated with a decrease in 
cardiovascular events41. Early CABG recovery patients tend to be relatively immobile, 
but mild exercise may elicit symptoms of pleural effusions. In addition to improving 
symptoms of breathlessness documented by mBORG, thoracentesis for pleural effusions 
have demonstrated an immediate increase in 6MWT distance15. For this reason, many 
studies assessing the effects of thoracentesis on pleural effusions measure outcomes using 
both the 6MWT and mBORG. 
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The goal of the present study is to randomly assign postoperative CABG patients 
to 1) a more frequent follow-up protocol and 2) a dedicated evaluation and treatment of 
pleural effusion. The purpose will be to assess the effect of these interventions on 30-day 
hospital readmissions, as well as to evaluate patient recovery in terms of 6MWT and 
mBORG. The control population will be assigned to standard postoperative patient 
follow-up four weeks after hospital discharge. If effusions are present and symptomatic, 
thoracentesis will then be performed. This group will also be assessed by 6MWT and 
mBORG. The information from this study may provide insight into lowering hospital 
readmission rates, thus decreasing hospital cost and patient mortality. 
1.4 Statement of Problem 
 
CABG is associated with frequent 30-day hospital readmissions. Within causes 
for early readmission among post-CABG patients, pleural effusions requiring therapeutic 
thoracentesis have been cited to be as high as 23%2. Despite this, to date there have been 
no randomized controlled trials among cardiac patients designed to reduce 30-day 
readmissions due to pleural effusions. Earlier and more frequent follow-up after 
discharge provides the ability to detect, monitor, and treat these effusions sooner. 
Furthermore, the excellent safety profile of ultrasound-guided thoracentesis allows 
providers to manage effusions in an outpatient setting. Together, an intervention 
consisting of earlier follow-up with concurrent management of pleural effusions may 
have a significant impact on rehospitalizations in this population. The proposed study 
provides a low risk, cost effective method geared towards improving patient outcomes.  




 With this study, we aim to examine the effect of earlier, more frequent follow-up 
including screening and protocolled treatment of pleural effusions on reducing 30-day 
hospital readmissions in patients discharged after CABG surgery. Two secondary aims 
are to determine if this intervention results in a change in 6MWT distance or mBORG 
rating, indicators of patient health that have been shown to correlate with hospital 
readmissions. We plan to examine this through a randomized controlled trial among 
patients undergoing CABG, a population in which pleural effusions are prevalent but 
treatment without rehospitalization is largely unstudied. This will provide original insight 
into the relationship between early management of patients and 30-day readmission in a 
population at high risk of rehospitalization.  
1.6 Hypothesis 
We hypothesize that increased follow-up with protocolled thoracentesis for 
pleural effusions in patients within 30 days of CABG surgery discharge will show a 
statistically significant decrease in 30-day hospital readmission rates when compared to 
the standard treatment. We propose that patients in the intervention group will have an 
improved 6MWT and mBORG at one month compared to those in the control group, in 
part due to management of pleural effusions. 
1.7 Definitions 
 
Protocolled thoracentesis: Ultrasound-guided thoracentesis in patients found to have a 
pleural effusion larger than or equal to 320ml in size or for effusions causing symptoms, 
namely dyspnea or chest pain. 
Standard follow-up regime: The standard timing and structure of follow-up utilized by 
the hospital upon discharge of CABG surgery patients. 
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Six-Minute Walk Test (6MWT): A test designed to measure the distance an individual is 
able to walk over a total of six minutes on a hard, flat surface. 
Modified BORG Scale (mBORG): A scale used to allow individuals to subjectively rate 
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Chapter 2 – Review of Literature 
2.1 Introduction 
 An extensive search of the literature was conducted between June 2019 and April 
2020 using PubMed, Ovid Medline, Cochrane, and ClinicalTrials.gov electronic 
databases. In order to identify articles involving pleural effusions found in post-coronary 
artery bypass graft patients, the following Medical Subject Headings (MeSH) terms were 
used: “coronary artery bypass graft surgery”, “pleural effusion”, and “thoracentesis” or 
“follow-up”. Other key search terms included 30-day readmission (early readmission), 
six-minute walk test (6MWT), BORG (modified BORG, mBORG), CABG (heart 
surgery, cardiac surgery), and thoracocentesis (fluid removal, drainage). Search criteria 
was limited to research available in the English language. To date, there are no published 
guidelines on management of post-CABG pleural effusions, and trials are limited on the 
subject. To increase the amount of information regarding benign pleural effusions, animal 
studies were also included in the data set. Abstracts were analyzed to determine article 
relevancy and those mentioning early or increased follow-up, thoracentesis, or pleural 
effusion in post-CABG patients were selected. Articles investigating pathology of benign 
pleural effusions were also included as supplemental material. Throughout the literature 
search, additional references were identified and obtained from citations in selected 
papers. Weight was given to randomized clinical trials and systematic reviews, however 
due to the fact that the topic remains largely unstudied, case series and retrospective 
observational studies were also included. 
 13 
 
2.2 Review of Empirical Studies 
 The following literature review will aim to analyze current research in three parts. 
First, data involving the effects of early and frequent follow-up on 30-day readmission 
rates in post-cardiac surgery and other high-risk patients will be reviewed. Randomized 
controlled trials investigating different follow-up methods yield conflicting conclusions 
on early readmission and thus need to be examined in depth. Second, because pleural 
effusions comprise a large number of potentially avoidable early readmissions in post-
CABG patients, the effects of early thoracentesis on outcomes that are associated with 
30-day readmissions will be discussed. Finally, data that combines early follow-up with 
prompt thoracentesis and resultant outcomes will be analyzed. Evidence for early 
thoracentesis in benign pleural effusions, including post-CABG, is extremely limited and 
needs to be further examined in large, prospective studies. Given the safety profile of 
thoracenteses and the identification of subclinical threats pleural effusions pose to the 
early recovery process in post-CABG patients, there is increasing data to justify the need 
for the proposed study. 
2.2.1 Studies Concerning Earlier and Increased Follow-up on 30-Day Readmission Rates 
 CABG is associated with a high number of post-operative acute care visits and 
30-day readmission rates, and many studies have focused on efforts to improve outcomes. 
Wong et al. studied the effects that home visits occurring within 7 days of hospital 
discharge had on 30-day readmission rates in “high risk patients”. Patients who had been 
hospitalized twice within 28 days (n=332) were randomized upon discharge to early 
home follow-up or standard outpatient follow-up scheduled within 4-6 weeks. The early 
home follow-up group received up to four home visits from community nurses within 28 
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days following discharge, with the first visit occurring by 7 days. The community nurse 
was able to identify health problems and resolve them or refer the patient back to the 
hospital for follow-up if necessary. Data was collected at baseline and 30 days after 
discharge by a researcher blinded to group allocation. The 30-day readmission rate in the 
study group was 58/166 (34.9%) compared to 62/166 (37.7%) in control, a non-
statistically significant (P = 0.648) result. However, the early-visit group experienced 
improved patient satisfaction with care (P = 0.025)1.  
 Limitations of this study are that the authors do not provide detail about timing of 
or reason for readmission in either group. Furthermore, the interventions able to be 
performed by visiting nurses were not disclosed, so it is difficult to know the scope of 
care provided to patients who had already been identified as high risk. Strengths of this 
study include the assessment of socioeconomic factors as possible confounders and 
choice of a setting where hospital care was easily accessible to both groups. 
Many factors could explain the lack of significance in the primary outcome 
results. Despite randomization, there were significant differences found between the two 
patient populations. Patients in the study group were on average older (72.5 years vs. 68.4 
years, P <0.001), retirees (89.8% versus 76.5%, P <0.014), receiving social welfare 
payments (84.3% versus 71.1%, P = 0.006), and had abnormal health assessments (91.6% 
versus 83.0%, P = 0.020). ANCOVA was performed to account for these differences 
between baseline variables and no statistically significant difference was found1. Notably, 
patients receiving social welfare did not need to pay for hospitalization, so it is possible 
that the intervention group had fewer economic barriers to readmission. Additionally, the 
authors suggest that the use of community nurses rather than advanced practice providers 
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or specially trained personnel may have limited the level of care available to the study 
population. 
In 2013, Nabagiez et al. recruited cardiothoracic physician assistants to perform 
home visits. In this randomized controlled trial, the authors evaluated 30-day readmission 
rates to a single hospital after assigning 701 cardiac surgery patients into physician 
assistant home care (PAHC) program or the hospital’s standard follow-up regimen. Both 
groups were seen in the office at 2 and 4 weeks after discharge. The control group was 
seen at home as needed by visiting nurses with no cardiac training. Patients in the PAHC 
group were visited at home on post-discharge days 2 and 5 by the same PA who treated 
them before and during their operation. This provided continuity of care to the 
intervention group and helped the PA choose appropriate care based on the patient’s 
recently observed baseline.  The investigators found that 16% (59/361) of the control 
group was readmitted versus 12% (42/340) in the study group, for a difference in hospital 
readmission of 25%. The authors documented interventions performed by the PAs and 
while most were medication adjustments – specifically diuretics – three chest x-rays were 
also ordered2. The results of the x-rays are unknown. 
 Despite these findings, the study was underpowered and results were found to be 
insignificant (P = .161). The authors suggest this is not only due to the low number of 
participants who completed the study, but also due to the low readmission rates in both 
groups. Notably, both groups were seen within 2 weeks of discharge, half the time that is 
commonly practiced. The data shows the most significant difference between 
readmission rates in the two groups during the first two postoperative weeks. 
Additionally, it shows a large spike in control visits during day 12-15. The early 
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difference can be attributed to PA visits and recognition of early problems on days 2 and 
5 in the intervention group. Whether the spike during days 12-15 could be combatted 
with another appointment at this time is plausible but unknown. 
 Dhalla et al. composed one of the largest randomized controlled trials on this 
subject to study the effects of frequent monitoring via a “virtual ward” on readmission or 
death in high-risk patients. The control group was discharged with recommendations for 
outpatient follow-up with their primary care or specialist physician whereas the 
intervention group was treated by the virtual ward team. The virtual ward consisted of a 
care coordinator, pharmacist, nurse or nurse practitioner, physician, and clerical assistant. 
This team was assigned to the patient upon discharge and met daily to design 
individualized care plans, which they then executed through phone calls, home visits, or 
clinic visits. Patients were contacted one day after discharge by phone, visited at home by 
a care coordinator within a few days of discharge, and able to be assessed by any member 
of the team as needed. On average, patients received 2.8 home visits (SD, 0.95) and were 
followed by the virtual ward for 35.5 days (SD, 27.0). The 30-day readmission rate in the 
study group was 18.9% (182/963) versus 21.3% (204/960) in the control group (P = .22)3. 
 This study addressed multiple limitations in the randomized controlled trials 
performed by Wong et al. and Nabagiez et al. Unlike in the study by Wong et al., all 
1,932 patients were randomized 1:1 in this trial, and the large sample size helped ensure 
similar patient characteristics in the groups. Patients in the intervention group were 
provided with an entire team who were able to increase frequency and duration of follow-
up as necessary, which in theory would have been useful given the high level of care 
provided. By using a team who was not affiliated with the discharging hospital, Dhalla et 
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al. attempted to create an intervention with generalizability. Unfortunately, this lack of 
connection with the discharging hospital made communication between providers and 
patient chart access difficult. This created a limitation in the team’s knowledge of what 
care had and was concurrently being provided to the patient, and may be responsible for 
the insignificant differences in readmission rates. Continuity of care, a strength 
highlighted by Nabagiez et al., was also nonexistent in this study as the intervention did 
not begin until patient discharge1-3. 
 With a design that builds upon the strengths of the prior three studies, Hall et al. 
created the “Follow Your Heart” (FYH) program to measure the effects of early post-
operative care by cardiac surgery nurse practitioners on 30-day readmission and death 
rates in post-CABG patients. The FYH intervention group, which consisted of 169 
patients, received two home visits within 7-10 days of discharge by a cardiac surgery NP 
who had been involved in the patient’s hospital care and recovery. The FYH program 
also consisted of phone calls, 24/7 phone availability by an on-call surgeon, and a routine 
office visit 10-14 days after discharge. NPs were encouraged to communicate with the 
patient’s providers regularly, which included sending pictures or questions to the cardiac 
surgeon or moving up appointments if needed. The control group, which consisted of 232 
patients, were instructed to return to the cardiac surgical clinic within 2 weeks of 
discharge for follow-up. 
 By providing continuity of care and early follow-up with an advanced practice 
provider specially trained in cardiac surgery, the authors were able to account for some of 
the limitations previously discussed. After propensity score matching, the control group 
showed a 30-day readmission rate of 11.54% (18/156) while the intervention group 
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showed a rate of 3.85% (6/156) (P=0.023), a statistically significant result. In the control 
group, 3/18 patients were found to be readmitted with pleural effusions, which the 
authors believe could have been treated with outpatient therapy4. 
 Echoing the results of the study by Nabagiez et al., there was also longer interval 
found between discharge and readmission in the FYH group (18.33 days) than control 
(8.94 days), highlighting the potential importance of visits beyond the first week of 
discharge. Unlike in the prior three studies discussed, the experiment by Hall et al. was 
unable to be randomized due to limitations in NP staffing and schedules. While it is 
possible selection bias occurred when forming the two groups, propensity score matching 
compensated for any confounding variables. Ultimately, the results from this study 
propelled the expansion of the FYH program into three system hospitals. 
 While we have identified different limitations in each of these studies, there are 
commonalities that highlight a benefit of increased, more frequent follow-up by 
specialized providers familiar with patients at high risk for early readmission. 
Additionally, the studies by Hall et al. and Nabagiez et al. address the ability to treat 
diagnoses commonly responsible for 30-day readmissions in post-cardiac surgery patients 
in the outpatient setting, but only Hall’s addresses the potential and significant impact of 
pleural effusions. As pleural effusions are prevalent among this population, further 
studies should be performed to evaluate the effects that treatment during early visits has 
on readmission rates. 
2.2.2 Studies Concerning Thoracentesis on Patient Outcomes 
 Many existing studies regarding thoracentesis focus on its impact on 
physiological functions. In 2007, Spyratos et al. studied the effects of thoracentesis on 
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expiratory flow limitation (EFL) at rest, a mechanism known to cause dyspnea in patients 
with chronic obstructive pulmonary disease (COPD). Twenty-one patients with unilateral 
pleural effusions underwent spirometry and negative expiratory pressure (NEP) testing 
before and after thoracentesis and a paired t-test was used to compare results. Prior to 
thoracentesis 14/21 (66.7%) patients were found to be flow limited in supine position. 
This number decreased to 5/21 (23.8%) of patients after thoracentesis (P = 0.013). 
Statistically significant differences were also observed in spirometry: forced vital 
capacity (FVC), forced expiratory volume in one second (FEV1), maximum mid-
expiratory flow, and inspiratory capacity all increased after thoracentesis (P <0.004). The 
mean volume of aspirated fluid was 1,581 ± 585ml, however the authors noted no 
correlation between volume of aspirated fluid during thoracentesis and improvement in 
spirometric parameters5. 
 A similar small study performed in 2011 by Cartaxo et al. studied the effects 
thoracentesis had on exercise capacity. Twenty-five patients with unilateral pleural 
effusions were subjected to spirometry as well as a six-minute walk test (6MWT) before 
and 48 hours after thoracentesis. By utilizing the 6MWT, the authors were able to assess 
a patient’s capacity to perform a mildly exertional activity rather than only at rest. A 
statistically significant improvement was found in FVC and FEV1 (P <0.001), echoing 
the results of Spyratos et al. Additionally, degree of dyspnea measured by mBORG 
significantly improved at rest (2.7 ±1.3 to 1.5 ±1.4) and during peak 6MWT (5.1 ±2.3 to 
2.4 ±1.6) after pleural fluid removal. Walking distance in 6 minutes increased by a mean 
of 63 meters (14.6%), bringing patients from 73.3% predicted in the presence of pleural 
effusion to 83.9% predicted after thoracentesis (P <0.001). The authors argued that the 
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improvement seen is substantial enough to allow a patient to return to their daily 
activities. Similar to the previous study, although the mean volume of fluid removed was 
1,564 ± 695ml, there was no correlation between volume of fluid drained and 
improvement in either 6MWT or mBORG6. 
 In 2012, Marcondes et al. examined the impact of thoracentesis on sleep quality in 
patients with unilateral pleural effusions. This study consisted of 19 patients with poor 
sleep quality at baseline, determined by the Pittsburgh Sleep Quality Index (PSQI) 
questionnaire and full polysomnography (PSG). Patients with dyspnea at rest, a need for 
supplemental oxygen, or persistent pain were excluded from the study. The group 
underwent at least two PSGs (six patients completed an additional PSG on the night prior 
to the first one to account for potential differences from “first night effect”), one on the 
night prior to drainage and one 48 hours later. The authors saw a statistically significant 
increase in sleep efficiency (from 76% to 81%, P = 0.006) and decreased percent of light 
(stage 1) sleep (from 16% to 14%, P = 0.002) following thoracentesis. They also recorded 
improvements in total sleep time (345 to 407 minutes, P = 0.054) and rapid eye 
movement (REM), or deep sleep (from 15% to 20%, P = 0.053). The mean volume 
drained was 1.624L ±796, however authors found no correlation between sleep efficiency 
and volume of pleural effusion drainage7. 
 Limitations of these studies include their small size and lack of randomized 
controlled nature. Pleural effusions often cause dyspnea at rest and these patients were 
excluded in the study by Marcondes et al., thus somewhat limiting generalizability. While 
these case series focus on subclinical symptoms that have been associated with higher 
readmission rates, the impact on hospitalizations was not studied. Notably, however, 
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thoracentesis lacked complications or side effects in these studies. Improvements were 
routinely seen across all three studies; however, outcome measurements were never 
associated with the volume of pleural fluid. Therefore, these results imply that even small 
volume thoracentesis may result in improved lung function and sleep, but studies are 
needed to confirm. 
2.2.3 Studies Concerning Earlier and Increased Follow-up with Thoracentesis on Patient 
and Hospital Outcomes 
 A clear combination of the two interventions examined in the prior sections 
comes from a randomized controlled trial performed by Hansen et al. This study 
addressed the poor 30-day outcomes in post-cardiac surgery patients by assigning 76 
patients scheduled to undergo CABG and/or aortic valve replacement surgery to either 
standard postoperative care or complementary follow-up visits that included clinical 
exams, focused chest sonography and protocol-driven thoracentesis, if applicable. All 
patients were seen the day before surgery (baseline) as well as 25-30 days post-
operatively, where they were examined and subjected to tests including the 6MWT. 
Patients assigned to the intervention group were seen for two additional visits: one at day 
3-4 and the other at day 10-15 post-op. Thoracentesis was performed in the intervention 
group if the estimated volume of pleural fluid was 400 ml or more, or if the patient was 
symptomatic with less fluid. Patients in the control group were subject to the standard 
regimen, which included thoracentesis only according to physician discretion. 
 A total of 45 pleural effusions were drained, 22 due to protocol and 23 as a result 
of x-ray screening or clinical indication.  Thus, point-of-care ultrasound improved 
detection of pleural effusions by 56%. The findings after thoracentesis were similar to 
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Cartaxo et al., with a mean immediate improvement of 81±42m (22%) found in the 
6MWT (P < 0.0001). The volume drained was 888±426 ml. Again, there was no 
correlation found between size of pleural effusion or either symptoms or 6MWT results. 
At the final visit, patients in the study group were found to have an improvement in 
physical recovery rate 15% higher than the control group, measured by mean change in 
walking distance when compared to baseline. Additional pathologies aside from 
postoperative effusions were discovered and treated in more than 20% of the study group 
during the two extra visits, which the authors also believed aided in recovery8. 
 By introducing a standardized pleural effusion protocol which included the 
drainage of small, asymptomatic pleural effusions, the authors enrolled patients for 
thoracentesis who are not regularly intervened on. Although they were unable to validate 
a clear cut-off volume for intervention, the results indicate that the study group as a 
whole benefitted from a lower threshold for intervention than is typically performed. 
With no justification as to why 400ml was chosen as the cut-off for intervention of 
pleural effusion, we question if thoracentesis on even smaller volumes could further 
improve outcomes. No individual data was reported, so we cannot evaluate changes in 
6MWT based on individual effusion size. The investigators also noted several limitations.  
First, only 21% of eligible patients enrolled. Second, a double-blind randomized trial was 
not possible due to the nature of the intervention. Third, it is unknown what happened in 
the control group regarding pleural effusions. Did some develop and then spontaneously 




 Hansen et al. addresses the known inverse relationship between decreases in 
6MWT and increases in cardiovascular events, recovery time, and rehospitalizations, yet 
these outcomes were not studied between groups. This study supports the use of 
thoracentesis on small, asymptomatic effusions discovered at more frequent follow-up 
appointments; however, a larger randomized controlled trial is necessary. Furthermore, 
although the intervention was shown to improve 6MWT, a study which correlates this to 
improved patient outcomes and reduced 30-day readmissions is needed to evoke a change 
in current management. 
2.3 Review of Studies to Identify Confounding Variables 
 Patients who have previously undergone heart surgery are more likely to have 
been exposed to patient education and self-care interventions. As a result, these patients 
may be more likely to have gained additional helpful behaviors through previous 
hospitalizations which could confound study results9. Additionally, increased length of 
hospital stay, number of bypass grafts, operative time in surgery, and complications 
during surgery have been found to be associated with higher odds ratio of early 
readmission10-12. These variables have also been correlated with decreased 6MWT 
distance13. Lastly, patients who utilize the hospital system repeatedly are at high risk for 
subsequent use of services14. Even with the proposed intervention, these patients may be 
more likely to present to the hospital and be readmitted. We will attempt to minimize 
variables by randomizing study participants and analyzing differences between groups. 
 Delayed outpatient follow-up has been associated with worse short-term and long-
term medication adherence in post-myocardial patients15. Although this association has 
not been studied in our population, most patients are discharged with new medications 
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after CABG surgery. These medications decrease the likelihood of complications from 
surgery and improve survival. In order to be enrolled in the study, patients must agree to 
attend follow-up if randomized to the intervention group. Patients who are more willing 
to attend follow-up appointments have been shown to have higher rates of medication 
adherence and are more likely to be invested in their own recovery, which may improve 
outcomes16. This could create a selection bias among participants. Furthermore, if merely 
having additional appointments scheduled reminds patients to take medication, practice 
incentive spirometry, and perform rehabilitation exercises, these confounding elements 
could act to improve 6MWT and reduce early readmissions without the intervention 
taking place. If these reminders occur at an appointment when patients undergo 
thoracentesis and the patient subsequently improves, it will be difficult to attribute 
positive outcomes specifically to thoracentesis. To help reduce potential confounders and 
further validate study findings, careful documentation of what interventions, if any, are 
performed at each follow-up visit will be kept. 
 CABG surgery itself has been shown to increase 6MWT distance17. By 
conducting the 6MWT and mBORG prior to surgery, improvements in both control and 
study groups are anticipated with retesting on day 25-30. Any improvement in these 
secondary outcomes noted in the intervention group has the potential to be confounded 
by the increase in coronary blood flow from CABG surgery and may not be associated 
with post-operative interventions. We will attempt to control for this with randomization, 
documentation of surgical factors, and careful comparison between groups. 
2.4 Review of Relevant Methodology 
This section serves to review literature relevant to the methodology. Please see 
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Chapter 3 for a more detailed description of the proposed study methods. 
2.4.1 Study Design Approach 
 The proposed study will be a prospective randomized controlled trial (RCT), 
which is the gold-standard in clinical research. Through this type of study, we will be 
able to determine if there is a causal relationship between early follow-up with 
protocolled thoracentesis and 30-day readmission rates. We will control for baseline 
characteristics between study groups. By incorporating randomization, we will minimize 
bias and confounding within our sample population.  
 RCTs are commonly used in studies assessing the effects of early or increased 
follow-up on patient readmission rates. This design, however, is much less common 
when assessing thoracenteses on patient outcomes, and most literature consists of case 
studies. Limitations of these studies include selection and information bias, small sample 
size, and lack of standards for pleural effusion volume drainage5-7,18. The lack of RCTs in 
this subject is largely due to ethical considerations, where symptomatic pleural effusions 
cannot be ignored in some patients to determine the effectiveness of thoracentesis. 
Additionally, previous methods of thoracentesis without ultrasound guidance resulted in a 
higher rate of complications, making this intervention unlikely to be performed on 
patients without symptoms19. Now that thoracentesis has widely been touted as low-risk, 
it is feasible to perform a RCT allocating patients to early intervention8. This design has 
been performed by Hansen, et al. and evaluated in the literature review above, and our 
proposed trial methodology is largely based off this work. 
 Given the nature of the proposed intervention, neither participants nor providers 
are able to be blinded. With objective primary and secondary outcomes, there is minimal 
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risk for bias. Regardless, we will attempt to control for any potential bias by blinding the 
evaluating researcher, who will assess outcome results without knowing if the patient 
received the intervention. 
 Although generalizability may be affected, the proposed trial will be conducted at 
a single center. The number of patients undergoing CABG surgery annually at Yale New 
Haven Hospital will be sufficient to show a significant effect and will require less 
personnel to staff initial and follow-up appointments. By using a single center, follow-up 
will also be streamlined and documentation will be easily accessible by researchers. 
2.4.2 Primary and Secondary Outcomes 
  An enormous amount of literature has focused on identifying risk factors in order 
to reduce 30-day readmission rates in patients after CABG surgery. Many studies have 
noted the high rate of pleural effusions in the readmitted population; however, to date 
none have evaluated the effects of early pleural effusion management on 30-day 
readmissions. For this reason, the primary outcome will be 30-day readmission rates in 
post-CABG patients assigned to early, more frequent follow-up with protocolled pleural 
effusion treatment compared to participants receiving current standard of care. This will 
be measured using hospital data as well as by asking all patients about readmission by 
telephone at 30 days after hospital discharge. Our assessment of 30-day readmission rates 
defined by hospital records is consistent with prior studies2,12,20-22, however conducting a 
brief phone call with the participant will account for any admissions to other hospitals 
within 30 days of discharge. 
 One secondary outcome of our study will involve analyzing lung function using 
6MWT. Patients in early recovery from CABG surgery are often on restricted activity or 
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bedrest, and 6MWT has been shown to uncover symptoms of pleural effusion that may 
go undetected at rest but can hinder recovery6. Increases in 6MWT distance have been 
associated with lower 30-day readmission rates23. The studied association between 
improvements in 6MWT and thoracentesis further link the intervention with our proposed 
outcomes6,8.  
The mBORG scale is often used concurrently to monitor self-perceived effort at 
rest and during exercise in cardiac patients24. Therefore, it will be administered to 
patients before and during the 6MWT and values will be compared between groups and 
evaluated as a secondary outcome. Complication rates following thoracentesis will also 
be evaluated. Lastly, to support the theory that follow-up visits during the first month do 
not serve merely to prolong readmission to the hospital, 60-day readmission rates will 
also be assessed with a brief phone call to each patient. 
2.4.3 Study Population and Recruitment Approaches 
 The selection of the academically distinguished Yale New Haven Hospital 
(YNHH) for the proposed trial was chosen due to its known high volume of annual 
CABG procedures. Additionally, YNHH has a CABG 30-day readmission rate of 17.3%, 
which is comparable to the national rate and high enough to observe a significant 
difference with our sample size. YNHH has cited their annual rate of CABG procedures 
to be around 574 patients, which is almost twice that of the sample size needed for our 
proposed study. 
 This study will assume that all patients scheduled to undergo CABG surgery who 
meet inclusion criteria will be enrolled. Patients undergoing emergency CABG 
procedures have been historically excluded from readmission studies due to the inability 
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to perform baseline assessments prior to surgery. Our study requires participants to be 
physically able to perform the 6MWT prior to surgery, therefore patients admitted for 
emergency CABG or those physically unable to complete the 6MWT prior to surgery 
will also be excluded from the study. For a more detailed account of the proposed study 
population, recruitment, and inclusion and exclusion criteria, please see Chapter 3. 
 2.4.4 Intervention 
 The traditional practice of conducting the first outpatient visit at 5-6 weeks 
following CABG hospital discharge is not evidence-based, and continues despite high 
hospital readmission rates occurring prior to the first appointment25. The lack of 
statistical significance in many studies examining the relationship between earlier patient 
follow-up and 30-day readmission rates has been repeatedly attributed to the same 
variables. Components named to be critical to patient rehospitalizations include 
establishing continuity of care, using appropriately trained providers, and obtaining 
access to patient information1-4,21. By employing trained cardiothoracic providers to 
perform initial patient assessment in addition to any follow-up appointments, this study 
ensures that personnel will be capable of addressing and treating post-operative 
complications. By utilizing the same providers both pre- and post-operatively, a visual 
baseline will be established, hospital course will be better understood, and appropriate 
continuity of care will be provided. These providers will be members of the 
cardiothoracic team handling the patient’s surgery, thus any patient information will be 
easily and instantaneously accessible. 
 Previous studies have demonstrated the importance of timing of follow-up within 
the first month. Given the increase in rehospitalizations seen during large gaps between 
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outpatient appointments, these studies provide evidence for more frequent follow-up in 
this time period2,3. Patient appointments on day 3-4, 10-15, and 25-30 following hospital 
discharge allow assessment and treatment of immediate and early post-surgical 
complications. The timing of these appointments also leaves limited time for new 
symptoms to develop and progress to the point of needing acute hospital care. 
 The use of ultrasound-guided thoracentesis has been widely accepted as the gold 
standard treatment for pleural effusions. Other methods of treatment involve higher risks 
of complications or lack immediate relief in symptoms19,26. While studies are in 
agreement about the procedure protocol, the indication for treatment varies widely 
between studies and, as a result, no established guidelines exist. Setting a predetermined 
cut-off volume for pleural effusion intervention provides an easily-followed, standardized 
approach that will ensure uniform treatment across the study group. Although no 
correlation was found between volume of pleural effusion and patient outcomes such as 
respiratory symptoms, sleep, or 6MWT, Usta et al. proposed that volumes lower than 
320ml were clinically insignificant, providing a cut-off for our study27. 
2.5 Conclusion 
 The studies reviewed surrounding the effect of earlier, more frequent follow-up 
on 30-day readmissions after CABG yields conflicting results with clear limitations. The 
existing evidence surrounding treatment for post-operative pleural effusions and the 
effects on various patient outcomes illustrate the potential benefit of early treatment, 
however they are underpowered and lack randomization. Taken together, these 
interventions have shown a potential to improve 6MWT in patients, which has been 
correlated with decreased cardiac events and hospitalizations. The evidence reveals an 
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unstudied area which has the potential to significantly decrease 30-day readmission rates 
in post-operative CABG patients, a population at substantial risk. The literature review 
has highlighted strengths and limitations of each study, which assists in the development 
of an adequately powered, randomized controlled trial designed to evaluate this two-part 
intervention on 30-day readmission rates. It also evaluates the methodology used to 
conduct a standardized study in this patient population with reliable and generalizable 
results. Lastly, the review aids in the development of secondary outcomes that will help 
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Chapter 3 – Study Methods 
 
3.1 Study Design:  
 
The proposed study is a single-center, prospective randomized controlled trial 
using convenience sampling among hospitalized adults scheduled to undergo elective 
coronary artery bypass graft surgery. Participants will be recruited and CABG surgery 
performed on a rolling basis over two years. Prior to beginning the study, an independent 
researcher will make four sets of 1:1 randomized allocations. The sets will be sealed in 
consecutively numbered opaque envelopes and patients will be randomized prior to 
surgery by opening the next sealed envelope.  
Patients will be randomized to frequent follow-up including protocolled treatment 
of pleural effusions (intervention group) or standard postoperative care (control group). 
Patients will be examined upon admission prior to surgery and a baseline 6MWT with 
mBORG scale will be administered. Patients in the intervention group will undergo 
postoperative clinic visits on day 3-4 (visit 1), day 10-15 (visit 2), and day 25-30 (visit 3) 
following hospital discharge. During these visits, patients will be assessed for pleural 
effusion using point-of-care ultrasound. Effusions ≥320ml or those causing symptoms 
will be promptly treated with thoracentesis. The control group will not be seen for a 
postoperative visit until day 25-30 following the current recommendations and 
thoracentesis will be performed at the physician’s discretion based on the patient’s 
symptoms.  
The data for the 30-day hospital readmission rate will be gathered from the 
hospital’s administrative record systems and by members of the study team contacting 
each study participant to correlate data. 
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3.2 Study Population and Sampling: 
 
The study will take place from January 2021 until July 2022. Convenience 
sampling will be used to enroll adults age ≥18 years old referred to undergo elective 
coronary artery bypass graft surgery at Yale New Haven Hospital. Primary indications 
for surgery will follow guideline recommendations from the American College of 
Cardiology (ACC)/American Heart Association (AHA). Inclusion criteria will consist of 
patients who have a planned CABG surgery, who are able to undergo a 6-minute walk 
test prior to surgery, and who consent to follow-up with the potential for one or more 
thoracenteses to be performed over the course of the month following surgery. The need 
for thoracentesis will be based on the size of the pleural effusion and will be performed if 
the size criteria is met (320 ml) but the patient appears asymptomatic. The patient must 
therefore be in a mental capacity to consent and have means for close clinic follow-up, 
such as transportation and support. 
Patients will be contacted and assessed for eligibility by study personnel 
following identification of qualified patients by clinical providers. The study rationale, 
risks, and benefits will be explained prior to obtaining written consent. Written consent 
for any thoracentesis deemed necessary during one-month follow-up period after surgery 
will be obtained concurrently. Once enrolled, all patients will undergo a 6MWT and 
evaluate self-perceived dyspnea using the mBORG scale prior to CABG surgery to 
establish a baseline of functional walking capacity and shortness of breath. All patients 
will again complete a 6MWT and mBORG scale during their final (day 25-30) visit. 
Patients will be excluded if undergoing emergency CABG or requiring 
concomitant cardiac surgery such as valvular replacement at the time of procedure. 
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Additional exclusion criteria include patients unable to perform baseline 6-minute walk 
test, patients being discharged with home hospice, and those simultaneously participating 
in other clinical trials. Patients will also be excluded from analysis if death occurs during 
initial admission. 
3.3 Subject Protection and Confidentiality: 
 
Prior to patient recruitment, approval for this study will be obtained from the 
Institutional Review Board (IRB) as part of the Human Research Protection Program at 
Yale University. Study participants will be given written information regarding the 
purpose of the trial, expected duration, and benefits and risks of participation, including 
the risks accompanying thoracentesis. The form will also describe the two treatment 
groups and randomization process. It will inform the patient of the required intervals for 
follow-up visits in each group. The patient may withdraw from the trial if at any point 
they are unsatisfied with treatment or no longer consent to outlined protocol. The patient 
may also refuse thoracentesis procedure at any time. Written consent will be required on 
an IRB-approved form prior to enrollment. 
Patient information will be kept strictly confidential under regulations of Health 
Insurance Portability and Accountability Act (HIPAA). Participating researchers will be 
required to undergo HIPAA training and certification. Electronic patient data collected 
over the duration of the study will be kept confidential on a server with data encryption 
software. All data will be deidentified and a randomly generated identification number 
will be used by researchers to identify participants. 




Study researchers will screen all hospitalized patients ≥18 years old at Yale New 
Haven Hospital scheduled to undergo coronary artery bypass graft surgery. Patients 
meeting eligibility requirements will be approached by recruiters and informed of study 
guidelines and implications of investigation. Due to time needed to obtain consent and 
gain baseline functioning with 6-minute walk test, patients admitted for emergency 
CABG will not be recruited. If the eligible patient is willing to enroll in the study and 
able to meet follow-up criteria outlined by the study, informed consent will be gathered. 
3.5 Study Variables and Measures:  
 
3.5.1 Exposure and Control Variables: 
The group subject to intervention will undergo more frequent follow-up with 
protocolled thoracentesis than the control group. Follow-up visits will occur 3-4 days 
(visit 1), 10-15 days (visit 2), and 25-30 days (visit 3) after initial hospital discharge. 
During follow-up visits, patients will undergo point-of-care ultrasound and 
accompanying thoracentesis if a pleural effusion ≥320ml or symptomatic pleural effusion 
is found. This will differ from the control group, which will attend only the 25-30 day 
follow-up and will undergo a thoracentesis at physician discretion. 
Additional variables to be obtained include the patients age, gender, race, 
ethnicity, and prior history of heart failure, renal failure, liver failure, malignancy, 
hypertension, or obesity. Body mass index (BMI) and pre-/post-operative list of 
medications will be recorded with anticoagulant use analyzed. A patient’s pre-operative 
INR, hemoglobin and platelet count will be recorded. Heart failure, renal failure, liver 
failure and malignancy may be associated with the development of pleural effusions. A 
patient’s BMI and use of anticoagulants have historically raised concerns of thoracentesis 
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complications, although recent studies have suggested safety1. Confounding variables are 
further described later in this manuscript (3.5.4). 
Any acute care visit, including to the clinic, emergency department, urgent care 
setting or other unplanned visit will be recorded as well as the reason for the visit.  
Special attention will be recorded for dyspnea, pleural effusion presence, congestive heart 
failure, renal failure, wound infection, and failure to thrive.  
3.5.2 Primary Endpoint: 
The main outcome for the study is 30-day readmission following discharge after 
coronary artery bypass graft surgery. Readmission is defined as a readmission to any 
hospital within 30 days of discharge from index hospitalization. Admissions for 
rehabilitation, hospital emergency department or urgent care visits, and transfers to and 
from another hospital are excluded from the definition although they will be recorded. 
3.5.3 Secondary Outcomes: 
 
 One secondary outcome of the study will be the 6MWT. This will be used as a 
measure of functional walking capacity and will provide insight into participant’s 
dynamic cardiopulmonary functioning. Patients will have six minutes to walk up and 
down a measured hard, flat surface (typically, the clinic hallway) as many times as 
possible. Following American Thoracic Society guidelines, the test will initially be 
conducted prior to surgery. The test will again be administered in all patients during 
follow-up day 25-30. During the test, patients will be made aware of each minute that has 
elapsed, but no encouragement will be given. The 6MWT will be immediately 
discontinued if patient experiences chest pain, dizziness or other symptoms precluding 
ongoing testing, with such reasons recorded. Additional secondary outcomes include 
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complication rates, mBORG scale for self-perceived dyspnea, and 60-day readmission 
rates. 
3.5.4 Confounding Variables: 
 
 Potential confounding variables within the study include age, gender, BMI, length 
of index stay, number of bypass grafts, type of bypass grafts, operative times in surgery, 
presence of DM, HTN, COPD, history of smoking, number of comorbidities, 
employment status, number of hospital admissions within the last 365 days, and 5-year 
average household income. After patient randomization, these characteristics will be 
assessed for differences between groups. 
3.5.5 Point of Care Ultrasound Method: 
 
A low-frequency (3-5 MHz) convex array probe connected to the Sonosite S-ICU 
ultrasound machine will be used to assess for pleural effusion. Patients will be in supine 
position with trunk elevation of 15˚. Effusion size will be estimated using the formula 
(Volume [ml] = 16 x parietal to visceral pleura distance [mm] at the mid-diaphragm). 
Two independent researchers will view each ultrasound to determine presence of pleural 
effusion and effusion volume. Symptomatic patients in either group will undergo prompt 
thoracentesis if pleural effusion is found. Patients allocated to the intervention group will 
also be subject to thoracentesis if determined to have an effusion ≥320ml, regardless of 
symptoms. 
3.5.6 Thoracentesis Method: 
 
If the patient is consented to undergo thoracentesis, the procedure will be 
ultrasound-guided and carried out using local anesthesia. A 6-French drainage catheter 
will be inserted into the pleural cavity and the effusion will be manually drained into a 
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collection bag, per protocol. The volume of fluid drained will be recorded. Drainage will 
cease when tap appears dry or the patient is unable to continue drainage due to pain or 
excessive cough, per clinical protocol. Patients will be observed for 30 minutes following 
procedure to ensure no complications. Patients will be sent home with information 
regarding their procedure and instructions to return in the event of worsening dyspnea. 
3.6 Blinding of Intervention and Outcome:  
 
 Due to the nature of the intervention, it is not feasible to blind patients or 
providers throughout the study. Patients will be told which group they have been 
allocated to prior to initial hospital discharge, and will thus either be seen for their first 
follow-up 3-4 days or 25-30 days after discharge. Providers assessing patients and 
performing thoracenteses during follow-up appointments (visit 1, 2, and 3) will be unable 
to be blinded to patient assignment. To control for information bias, primary and 
secondary outcome assessment will be performed by a researcher blinded to group 
allocation. 
3.7 Assignment of Intervention:  
 
 Participants who meet inclusion criteria will be randomly allocated to either the 
intervention or control group in a matched 1:1 ratio following randomization protocol 
outlined above. Prior to obtaining consent, patients will be informed of both group 
assignments and will agree to participate in the study regardless of group allocation. As 
mentioned, neither patient nor researcher conducting follow-up visits can be blinded to 
the intervention, however researchers analyzing outcome data will be blinded. Further 






 All study participants will be evaluated 25-30 days following index 
hospitalization discharge to assess for adherence to follow-up protocol. Documentation 
from each follow-up visit including ultrasound findings and procedure codes will be 
accessed for patient and physician adherence. If patients assigned to the intervention 
group do not present to either visit 1 or 2, this will be documented. To prevent participant 
dropout due to missed appointments, members of the research team will contact 
participants via telephone two days prior to each appointment. Attempts to reschedule 
patients within the follow-up appointment windows will be made if participants are 
unable to attend scheduled appointments. If at any point patients refuse recommended 
thoracentesis, this will also be documented. 
3.9 Monitoring of adverse events:  
 
 Following thoracentesis, patients will be monitored for 30 minutes for adverse 
effects. A chest x-ray will be obtained if there is any concern about complications that 
occurred as a result of the procedure. In this trial, adverse effects will include 
pneumothorax, bleeding, or infection after thoracentesis. Patients will be discharged 
home with information regarding pleural effusions and warning signs that should prompt 
the patient to contact their provider. Any complication arising during follow-up visits that 
results in rehospitalization, patient disability, or requiring intervention to prevent 
permanent patient impairment will be documented and reported. 
3.10 Data collection:  
 
 Patients referred for CABG who have met study eligibility criteria will meet with 
researchers to obtain initial 6-minute walk test and dyspnea data and undergo 
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randomization into either control or intervention group. Patient data including age, 
gender, BMI, presence of DM, HTN, COPD, history of smoking, number of 
comorbidities, and 5-year average household income will be gathered. During the 
operation, number of bypass grafts, type of bypass grafts, and operative time will be 
recorded by a researcher. Prior to discharge, group allocation will be discussed with 
patient and follow-up visits will be scheduled and recorded.  
 Data in the form of readmissions to Yale New Haven Hospital will be collected 
for 30 days following a patient’s initial discharge. During the 25-30 day follow-up visit, 
patients will again undergo a 6MWT with mBORG rating and data will be recorded by a 
researcher blinded to patient allocation. A researcher will contact patients by phone at 
day 30 and day 60 to inquire about any hospitalizations since CABG discharge. 
3.11 Sample size calculation:  
 
 The incidence of 30-day readmission in CABG patients is cited to be 16.5%2. The 
proposed study assumes an absolute difference in incidence of 30-day readmission rate of 
66%, as shown in other studies of 30-day readmission rates among the same patient 
population2. Utilizing Power and Precision statistical software, a difference of proportion 
calculation was performed assuming a 2-tailed hypothesis, alpha of 0.05, and power of 
80%, yielding a sample size of 126 patients per group. A minimum of 252 patients would 
be required for enrollment, however the final sample size will also account of an 
estimated 20% dropout rate as evidenced by other literature. Thus, a total of 303 patients 




 Descriptive variables will include confounding variables previously mentioned 
(3.5.4). Student’s T-test will be utilized for comparison of continuous variables, which 
will be reported as a mean (standard deviation) or median (interquartile range). Chi-
square testing will be used for comparison of categorical variables, which will be 
reported as frequencies. Readmissions at 30 days will be reported as a frequency. 
Baseline patient characteristics will be collected and recorded during the initial pre-
surgical visit. Hospital course and CABG procedure characteristics including length of 
index stay, number of bypass grafts, type of bypass grafts, and operative times in surgery 
will be obtained during post-op day 25-30 visit. All statistical tests will be two-tailed, and 
deemed significant if P-value ≤0.05 is reported. Intention-to-treat analysis will be used. 
Data will be evaluated using Statistical Analysis software. After randomizing and 
matching patient characteristics to account for confounders, univariate models will be 
used to analyze the outcome of interest. If significant discrepancies are found between 
groups, we will use multivariate analysis.  
3.13 Timeline and Resources: 
 This study will be performed over a two year time period. Enrollment and hospital 
index will occur over an 18 month period, beginning January 2021. Data collection will 
continue for 30 days following discharge of the final patient enrolled. The last follow-up 
visit will be completed by August 2022, reserving the final four months for statistical 
analysis. Each patient enrolled will be analyzed independently by research assistants on a 
continuous basis depending on date of hospital index. The proposed research study will 
require two cardiothoracic providers trained in ultrasound-guided pleural effusion 
diagnosis and management. These providers will be dedicated to recruiting patients, 
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performing pre-operative evaluation, and conducting post-operative outpatient visits. An 
additional two personnel will be needed to schedule patients for follow-up appointments 
and send phone call reminders, perform chart review, assess for primary and secondary 
outcomes, and call patients at post-hospital discharge day 30 and 60. A final two 




1. Puchalski JT, Argento AC, Murphy TE, Araujo KLB, Pisani MA. The Safety of 
Thoracentesis in Patients with Uncorrected Bleeding Risk. 2013;10(4):336-341. 
2. Hall MH, Esposito RA, Pekmezaris R, et al. Cardiac Surgery Nurse Practitioner 
Home Visits Prevent Coronary Artery Bypass Graft Readmissions. The Annals of 
thoracic surgery. 2014;97(5):1488-1495. 
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Chapter 4 – Conclusion 
4.1 Study Advantages and Disadvantages 
 The major strengths of this study lie in its novel clinical design. Evaluations of 
30-day CABG readmissions have cited pleural effusions requiring thoracentesis as a 
major cause, however no studies to date have examined the effect drainage has on this 
outcome. Past studies exploring thoracentesis on other outcomes have lacked significant 
sample size, randomization, and control groups. These studies have also failed to identify 
a clinical cut-off volume for which thoracentesis is no longer beneficial. 
 The proposed study is the first randomized controlled trial to evaluate increased 
follow-up with protocolled pleural effusion management on 30-day readmission rates in 
CABG patients. By randomizing participants, we will decrease potential selection bias 
and strengthen generalizability of results. The use of a protocolled plan which includes 
volume of pleural effusion warranting thoracentesis will provide consistent, objective 
data free of operator variables.  
 Earlier outpatient follow-up in CABG patients will allow closer monitoring and 
treatment of adverse effects not strictly limited to pleural effusions. This could potentially 
avoid more serious complications or lead to earlier treatment if the patient still requires 
hospitalization. By establishing contact with the patient prior to CABG, the examiner will 
have a baseline assessment and be able to provide meaningful continuity of care. This 
study also proposes a low-risk, ethical intervention. The simplicity of bedside ultrasound 
combined with outpatient appointments ensures a low-cost practice that can be widely 
implemented if found to significantly improve outcomes. 
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 With the nature of the intervention comes potential limitations. Patients and 
investigators are unable to be blinded in this study. Due to ethical concerns, any adverse 
outcome that is able to be intervened upon during outpatient visits will be addressed, 
potentially lowering hospital readmission rates regardless of pleural effusion presence. 
Additionally, it would be unethical to monitor symptomatic pleural effusions without 
intervention. These interventions will be rigorously reported. 
 In order to obtain baseline 6MWT and mBORG data from patients in both groups, 
these variables will be measured during the initial enrollment meeting prior to CABG 
surgery. Follow-up data collection will occur during day 25-30, when the control group is 
first seen after hospital discharge. Due to timing of initial evaluation, any improvements 
seen in these secondary outcomes may exist due to increased coronary blood flow from 
CABG surgery, independent of the proposed intervention.  
 The study may be affected by large drop-out rates. Brooke et al. found that older 
patients were less likely to attend outpatient follow-up appointments if they believed the 
appointments would not add value1. This has the potential to remove patients from the 
study who are recovering without complication and would thus contribute to lower 
readmission rates in the intervention group. Additionally, asymptomatic patients in the 
intervention group with effusions ≥320ml may not consent to a thoracentesis procedure, 
which would result in their removal from the study. 
 Despite significant attention given to patient population and resources, there are 
still aspects of the study that limit generalizability. First, the study will be conducted at a 
single center. Second, thoracentesis will be performed by a trained provider who has been 
involved in the patient’s cardiothoracic care. Low complication rates have been reported 
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when experienced operators are utilized, however this may not always be available 
outside of the study institution. 
4.2 Clinical and Public Health Significance 
 30-day readmission rates after CABG surgery are extremely high. These 
readmissions are also extremely costly to the hospital system and at risk of no longer 
being reimbursable by insurance companies. This has prompted numerous trials designed 
to reduce rehospitalizations, however conflicting evidence and lack of prospective nature 
have yielded no change in practice. Unfortunately, while patients undergo CABG with 
the goal of improving their health, pleural effusions are a common complication from 
surgery that often bring patients back into the hospital. With readmission, patient 
mortality rate increases, recovery rate slows, and patients are put at higher risk for 
infection2. 
 If successful, this study would provide evidence to suggest a change in the way 
providers follow-up on hundreds of thousands of patients every year. The introduction of 
earlier follow-up with a provider who has seen the patient prior to surgery will also 
provide continuity of care and allow any concerns or early symptoms to be addressed and 
treated. The results of this study may also help establish guidelines for the treatment of 
benign pleural effusions, which to date is subject to significant variability due to its 
dependence on clinician discretion. Outpatient ultrasound screening and treatment for 
pleural effusion is a low-cost procedure that has the potential to save a hospital millions 
of dollars per year. Further studies to identify whether even smaller volume pleural 
effusions benefit from drainage may be warranted. The proposed intervention of this 
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study may be effective in reducing 30-day CABG readmissions and with it patient 
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APPENDIX A: Sample Consent Form 
 
CONSENT FOR PARTICIPATION IN A RESEARCH PROJECT 
200 FR.1 
YALE UNIVERSITY SCHOOL OF MEDICINE 
Study Title: EARLY THORACENTESIS AND FOLLOW-UP IN CORONARY ARTERY 
BYPASS GRAFT PATIENTS 
Principal Investigator: Jonathan Puchalski, MD, Med and Jessica Kohler, PA-SII 
Funding Source: Yale School of Medicine 
 
 
Invitation to Participate and Description of Project 
 We are inviting you to participate in a research study designed to investigate the 
relationship between early outpatient follow-up paired with protocolled thoracentesis and 
the possible decrease of 30-day hospital readmissions. You are being asked to participate 
because you are at least 18 years of age and are scheduled to undergo elective coronary 
artery bypass graft (CABG) surgery. Approximately 300 individuals will be participating 
in this study. 
 In order to decide whether or not you wish to be a part of this research study, you 
should know enough about its risks and benefits to make an informed decision. This 
consent form gives you detailed information about the research study, which a member of 
the research team will also discuss with you. This discussion should take place over all 
aspects of this research study—its purpose, procedures that will be performed, any 
potential risks of the procedures, possible benefits, and possible alternative treatments. 
Once you understand the study, you will be asked if you wish to participate. If you agree, 
you will be asked to sign this form. 
 
Description of Procedures 
If you agree to participate in this study, no change will occur to your planned 
CABG procedure or subsequent hospital stay. During today’s visit, we will ask you to 
perform one 6-minute walk test. For this, you will be asked to walk as far as you can in 
six minutes with the distance and your oxygen saturations being recorded.  We will also 
ask you to determine how short of breath you are using a scale from 0-10.  These are tests 
that are not performed for people who do not consent to participating in the study. 
All patients will have a follow-up appointment 25-30 days after discharge from 
the hospital.  You will be randomly assigned to receive either (a) additional outpatient 
follow-up on day 3-4 and day 10-15 following hospital discharge with accompanying 
treatment for any pleural effusions found to be symptomatic or ≥320ml in size, OR (b) 
standard outpatient follow-up on day 25-30. During your follow-up appointment on day 
25-30, all patients enrolled will again undergo a 6-minute walk test and fill out the 
modified Borg scale. 
If you are randomized to the additional follow-up group (a), you will attend three 
outpatient appointments (on day 3-4, day 10-15, and day 25-30 post-discharge) where 
you will be evaluated by a cardiothoracic surgery provider. During the appointment, your 
provider will assess for any pleural effusions using a handheld ultrasound probe. If 
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pleural effusions are present, your provider will determine the size and assess you for 
symptoms. Any effusion found to be causing symptoms or ≥320 ml during these visits 
will be promptly drained using thoracentesis method, described below. During your visit, 
your provider will ask about your recovery and any additional symptoms you may be 
experiencing. They may adjust your medications if necessary. 
If you are randomized to standard follow-up group (b), you will only attend the 
standard outpatient appointment 25-30 days after hospital discharge. During this 
appointment, your provider will ask about your recovery and any additional symptoms 
you may be experiencing. If you are having symptoms including difficulty breathing, 
shortness of breath, or dry cough, your provider may assess for a pleural effusion using a 
handheld ultrasound probe. An effusion found to be responsible for symptoms will be 
drained using thoracentesis if your provider deems it to be necessary. During this visit, 
your provider may also adjust medications if necessary. 
Both groups (a) and (b) will undergo another 6-minute walk test and rate self-
perceived dyspnea during the standard outpatient follow-up appointment 25-30 days after 
hospital discharge. During this visit, you will be asked if you have been readmitted to the 
hospital at any time during the month. You will also receive a follow-up phone call at day 
60 asking if you had an unplanned visit or admission to the hospital during this time and 
if so, the reason for readmission. 
In this study, you will be asked to adhere to your assigned medication regimen 
and recovery exercises at the prescribed frequency and dosage. The total amount of time 
of enrollment in this study would be 1 month following your CABG hospital discharge, 
with one additional phone call at 2 months. 
A description of this study will be available on http://www.ClinicalTrials.gov, as 
required by U.S. Law. This website will not include information that can identify you. 
The purpose of this database is to allow everyone to see information on what studies are 
being done, and what studies have already been done. At most, the website will include a 
summary of the results. You can search this website at any time. 
You will be told of any significant new findings that are developed during the 
course of your participation in this study that may affect your willingness to continue to 
participate. Research results will not be returned to your clinician. If research results are 
published, your name and other personal information will not be disclosed or given. 
 
Thoracentesis Procedure 
 This procedure removes fluid that has built up in the space between the lungs and 
ribs (called a pleural effusion). During this procedure, the area where the needle goes is 
numbed by an injection of a local anesthetic. The needle then goes through the skin, 
between the ribs and into the fluid around the lung. A catheter is advanced over the 
needle and the fluid is removed. At the end of the procedure, the catheter is taken out. A 
dressing is put over the area. If you have new symptoms following the procedure, a chest 




Fig 1. National Heart, Lung, and Blood Institute 
 
Risks and Inconveniences 
 In recommending this procedure, your provider has balanced the benefits and 
risks of the procedure against the benefits and risks of not proceeding. Your provider 
believes there is a net benefit to the procedure. Symptoms during and after the procedure 
are uncommon, but include shortness of breath, coughing, fainting, or pain. Rare risks 
and complications include bleeding into the space between the lungs and ribs, the build-
up of air or fluid into the lung, damage from the needle to nearby parts of the body (i.e. 
liver or spleen), collapsed lung which may require chest tube insertion to reinflate the 
lung, wound infection, thrombosis, or in extremely rare cases, death. The overall risk of 
complications from a thoracentesis is less than 1%. 
Other risks from participating in the study include the breach of confidentiality 
about your health status and participation in the study. This is unlikely to happen, as all 
study investigators are trained and certified in research privacy, as well as HIPAA. 
 
Benefits 
The potential benefit resulting from the study is a decrease in the chance of being 
readmitted to the hospital after CABG surgery, especially during the first 30 days after 
discharge when readmissions are common. Other benefits include closer follow-up with 
your cardiothoracic provider, where you will be able to have any symptoms or concerns 
addressed and treated promptly. By undergoing immediate treatment of pleural effusions 
found during your outpatient visits, you may be less likely to suffer from discomfort or 
symptoms which slow your post-surgical recovery. 
 This study may also provide better insights to treatment guidelines for patients 




No compensation will be made to subjects enrolled in this study. You will still be 
responsible for any co-pays required by your insurance company for standard treatment. 
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There are no other costs associated with your participation in the study. Parking at your 
follow-up appointments will be provided free of charge. 
 
Treatment Alternatives/Alternatives 
If you choose not to participate in this study, you will receive the current standard 
follow-up at Yale New Haven Hospital. This means you will schedule a follow-up 
appointment with your provider 25-30 days following hospital discharge to assess how 
you are recovering. 
 
Confidentiality and Privacy 
Any identifiable information that is obtained in connection with this study will 
remain confidential and will be disclosed only with your permission or as required by 
U.S. or State law. Examples of information that we are legally required to disclose 
include abuse of a child, abuse of an elderly person, or certain reportable diseases. 
Information will be kept confidential by using only identification numbers on study 
forms, storing signs forms in locked cabinets, and password protecting data to be stored 
on a computer. When the results of the research are published or discussed in 
conferences, no information will be included that would reveal your identity unless your 
specific permission for this activity is obtained. 
We understand that information about your health is personal and we are 
committed to protecting the privacy of that information. If you decide to be in this study, 
the researcher will get information that identifies your personal health information. This 
may include information that might directly identify you, such as name, address, 
telephone number, email address, and/or mobile phone number. This information will be 
de-identified at the earliest reasonable time after we receive it, meaning we will replace 
your identifying information with a code that does not directly identify you. The principal 
investigator will keep a link that identifies you and your coded information. This link will 
be kept secure and available only to the principal investigator, or selected members of the 
research team. Any information that can identify you will remain confidential. 
Information will be kept confidential by using only identification numbers on study 
forms, storing signed forms in locked cabinets, and password protecting data stored on a 
computer. The research team will only give this coded information to others to carry out 
this research study. The link to your personal information will be kept for five years. 
After five years, the link will be destroyed, and the data will become anonymous. The 
data will be kept in this anonymous form indefinitely. 
The information about your health that will be collected in this study includes: 
• Research study records 
• Records about phone calls made as part of this research 
• Records about your study visits 
By signing this form, you authorize the use and/or disclosure of the information 
described above for this research study. The purpose for the uses and disclosures you are 
authorizing is to ensure that the information relating to this research is available to all 
parties who many need it for research purposes. 
All healthcare providers subject to the Health Insurance Portability and 
Accountability Act (HIPAA) are required to protect the privacy of your information. The 
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research staff at the Yale School of Medicine are required to comply with HIPAA and to 
ensure the confidentiality of you or your child’s information. 
If you choose to participate in this study, the investigators will check your 
electronic medical record at Yale via EPIC to make sure you qualify. Any access to your 
electronic medical record will be done consistent with HIPAA regulations. 
You have the right to review and copy your health information in your medical 
record in accordance with institutional medical records policies. This authorization to use 
and disclose your health information collected during your participation in this study will 
never expire. 
 
Voluntary Participation and Withdrawal 
Participating in this study is voluntary. You are free to choose not to take part in 
this study. Your healthcare outside the study will not be affected if you do not agree to 
participate. However, you will not be able to partake in this research study and will not 
receive study procedures as a participant if you do not allow use of your information as 
part of this study. You do not give up any of your legal rights by signing this form. 
If you do become a subject, you are free to stop and withdraw from this study at 
any time during its course. To withdraw from the study, you can call a member of the 
research time at any time and tell him or her that you no longer wish to participate. This 
will cancel any future appointments. 
When you withdraw your permission, no new health information identifying you 
will be gathered after that date. Information that has already been gathered may still be 
used and given to others until the end of the research study, as necessary to ensure the 
integrity of the study and/or study oversight. 
The researchers may withdraw you from participating in the research, if 
necessary. This will only occur if you do not adhere to the assigned treatment. 
If you choose not to participate, or if you withdraw, it will not harm your 
relationship with your treatment team or with the Yale New Haven Hospital. 
 
Questions 
We have used technical and/or legal terms in this form. Please feel free to ask about 
anything you do not understand and to consider this research and the permission form 




I have read, or someone has read to me, this form and have decided to participate in the 
project described above. Its general purpose, the specifics of my involvement, possible 
hazards, and possible inconveniences have been explained to my satisfaction. My 
provider has also explained the thoracentesis procedure and I understand the risks, 
including the risks that are specific to me. I understand that no guarantee has been made 
that the procedure will improve my condition. I understand that I have a right to change 
my mind at any time, including after I have signed this form, but preferable following a 
discussion with my provider. My signature indicates that I have received a copy of this 
consent form. 





__________________________________  ____________________ 
Signature of Person Obtaining Consent  Date 
 
If you have any further questions about this project, or if you have a research-related 
problem, you may contact the Principal Investigator, Dr. Jonathan Puchalski, or co-
investigator Jessica Kohler, PA-SII. 
If, after signing this form, you have any questions about your privacy rights, please 
contact the Yale Privacy Officer at 203-432-5919. If you would like to talk to someone 
other than the researchers to discuss problems, concerns, and/or questions you may have 
regarding the research, or to discuss your rights as a research subject, you may contact 




APPENDIX B: mBORG Scale of Perceived Exertion 
 
Instructions:  
This scale is used to determine if you feel short of breath at rest and with exercise. 
 Using the scale below, please rate your level of breathlessness from 0, meaning 
no shortness of breath, to 10, meaning maximal breathlessness.  
 
 
Scoring Description Shortness 
of Breath at 
Rest 
Shortness of Breath 
with Exertion 
0 No breathlessness at all ☐ ☐ 
0.5 Very, very slight (just 
noticeable) 
☐ ☐ 
1 Very slight ☐ ☐ 
2 Slight breathlessness ☐ ☐ 
3 Moderate ☐ ☐ 
4 Somewhat severe ☐ ☐ 
5 Severe breathlessness ☐ ☐ 
6  ☐ ☐ 
7 Very severe breathlessness ☐ ☐ 
8  ☐ ☐ 
9 Very, very severe (almost 
maximal) 
☐ ☐ 












APPENDIX C: Sample Size Calculation 









Rate Difference 0.11 
N Per Group 126 
Number of Groups 2 
Total Required Participants 252 
Standard Error 0.039 
95% Lower 0.034 
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